Alembic Reports Strong Q1 FY27 Results; Revenue Rises 26% Amid US and API Growth

Alembic Reports Strong Q1 FY27 Results; Revenue Rises 26% Amid US and API Growth​

Alembic Pharmaceuticals Limited has reported robust financial performance for the quarter ended June 30, 2026. The company saw its total revenue increase by 26%, driven by significant growth across its US Formulation and API businesses.

The quarterly results reflect substantial operational achievements, with Total Income reaching INR 21.65 billion. Revenue from Operations stood at INR 21.50 billion, showing a 26% year-over-year (YoY) rise and a 16% quarter-on-quarter (QoQ) increase. Profit Before Tax (PBT) saw a 17% YoY jump, reaching INR 2.22 billion.

Q1 Financial Highlights​

The financial snapshot for the quarter shows continued margin expansion across various operational metrics:

Segment Performance Details​

Formulations Business
The formulations portfolio saw a healthy expansion, with revenue reaching INR 21.50 billion in Q1 FY27. The performance across different segments was as follows:


The India Branded Business generated INR 6.42 billion, achieving 7% YoY growth. The US Formulation segment led the charge with 49% YoY growth, attributed to key product launches and increased volumes. The API business recorded a strong 33% YoY growth, supported by an active order book.

India Branded Business Performance
The India Branded Business holds a 1.1% market share in the Indian pharmaceutical space and is ranked 21st in the Indian Pharmaceutical Market (IPM). Of its product portfolio, 13% is listed under NLEM. The company's prescription volume ranking was Q3 on the national scale, with a 6.4% MS% in Q1 FY27.

Key brands maintaining leadership status include AZITHRAL and CRINA-NCR (both Rank 1), while ESTROPLUS, ISOFIT SR, and TRAVISIGHT were ranked 2nd.

International Segments and Animal Health
The US Business has a strong customer base in the established US market. In Q1 FY27, Alembic launched 7 products, bringing its commercialized product count to 185. The Ex-US business achieved 17% YoY growth in Q1 by focusing on targeted execution and retaining global demand. The company is expanding its international presence through a joint venture (JV) in Canada and new subsidiaries established in Thailand, the Philippines, and Germany.

The Animal Health division recorded 23% growth in the quarter. Alembic operates across Livestock, Poultry, and Companion Animal segments, and holds market leadership in Haematinics and Antibiotics with brands such as Sharkoferrol and Moxel.

R&D and Manufacturing Strengths
Alembic maintained a focus on R&D investment, with expenses reported at 9% of revenue. The company continues to build its product pipelines in both Formulation and API segments.

The robust infrastructure includes multiple manufacturing sites:


In addition, the company's formulation center in Indore has undergone a successful WHO audit.

APLLTD Stock Price Movement​

Alembic Pharmaceuticals Limited shares climb as of 2:33 PM, currently trading at ₹813.35 after gaining 0.94%. The stock has seen a volume of 257,051 shares during the live market session.